The FDA has set a Prescription Drug User Fee Act target action date of Aug. 22, 2026. ・The application is backed by data from the Phase 2 Hope-2 trial and the Phase 3 HOPE-3 trial. ・Earlier, Capricor ...

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors of the September 15, 2025 deadline to seek the role of lead ...

As of Friday, July 10, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 5.07%, which has investors questioning if ...

Fresh filings showed CFO Anthony Bergmann and legal chief Karen Krasney sold about $1.46 million in shares on June 25. ・Both executives exercised 24,100 options at $3.18 and sold the shares at an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock ...

Capricor Therapeutics (CAPR) closed the last trading session at $18.09, gaining 330.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Capricor Therapeutics Inc (NASDAQ: CAPR) shares are trading higher Tuesday after the company announced intent to file a biologics license application (BLA) for the full approval of Deramiocel for the ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...